Director – Companion Diagnostics
Remix Therapeutics
Director – Companion Diagnostics
Remix Therapeutics
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).
Position Summary:
The Director for Companion Diagnostics will drive cross-functional alignment of biomarker operations, clinical development, regulatory & quality expectations with external device & In vitro diagnostic (IVD) partners to deliver fit-for-purpose devices that meet global regulatory requirements and support clinical decision-making. This individual will serve as a key partner to cross-functional teams leading CDx development through IVD clinical validation & requirements for registration, approval, and launch ensuring timely availability of high-quality devices and IVDs aligned with drug development milestones.
Key Responsibilities:
Qualifications:
Salary Range:
$206,000 - $252,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.
Explore more opportunities at Remix Therapeutics